Exelixis's financial performance in Q4 2024 is not currently available, and the company's reported figures are from Q3 2024. However, we can infer potential trends based on the available data.
- Revenue Growth: Exelixis saw a significant year-over-year increase in revenue for Q3 2024, with reported revenues reaching $539.54 million, a 14.3% rise from the same period in the previous year1. The company had earlier revised its 2024 revenue guidance upward to $2.15 billion-$2.2 billion, up from $1.975 billion-$2.075 billion, following strong sales of Cabometyx2. This indicates a favorable revenue trajectory that could potentially continue in Q4 2024.
- Cost Management: Exelixis reported a decrease in research and development expenses to $222.6 million in Q3 2024, down from $332.6 million in the same period of 20233. Selling, general, and administrative expenses also decreased to $111.8 million, compared to $138.1 million in Q3 20233. This suggests a trend towards cost management and efficiency improvements within the company, which could positively impact net income in Q4 2024.
- Net Income Improvement: The company's GAAP net income for Q3 2024 was $118 million, a significant increase from $1 million in Q3 20233. Non-GAAP net income was even more robust at $135.7 million, compared to $32.1 million in the prior year's same quarter2. Given these improvements and the revenue growth trajectory, it is likely that Exelixis's net income in Q4 2024 could be substantial, assuming no significant changes in cost structure or operating expenses.
In conclusion, Exelixis is on a positive financial trajectory for Q4 2024, with revenue expected to grow and costs under control, suggesting a strong potential for increased net income.
5/7/2025 09:44am
